Anthea pharma operates as a Global Sterile injectable CDMO with facilities for vials, prefilled syringes, ampoules, emulsions, suspensions and lyophilized products. Its world-class R&D center supports formulation development, analytical methods, and regulatory compliance for global markets. The manufacturing facility received USFDA approval following a successful inspection in July, 2024, confirming compliance with high-quality standards for sterile injectables.

Company (Headquarters):

India

Types of Drugs Manufactured:

Small Molecule;Medical Devices;Nutraceuticals

CDMO Services:

Drug Product/FDF;Research & Development;Packaging(Commercial);Regulatory Services;Analytical Development;Packaging (Clinical);Process & Forumulation Development;Supply Chain Logistics

Therapeutic Area:

Cardiovascular;Central Nervous System;Diagnostics and Monitoring;Digital Health;Ear Nose Throat and Oral health;Endocrine and Hormonal;Gastrointestinal and Metabolism;Genito Urinary and Women’s Health;Hematology;Immunology;Infectious Disease;Medical Devices;Musculoskeletal System;Nutritional;Platform Technologies;Radiopharmaceuticals;Rare and Genetic Disorders;Respiratory;Wounds and Injuries;Pain Symptoms

CDMO Number of Facilities:

1

High Potent Products capabilities:

OEB 3 Medium Potency;OEB 4-5 Highly Potent APIs (HPAPIs);OEB >5 Ultra high potency

Facilities Location:

South Asia

Regulatory Approvals for facilities:

USA – FDA;GMP;India – CDSCO;WHO

Manufacturing Technologies:

Cartridges;Lyophilized amps/vials;Pre-Filled Syringes (PFS);Sterile Ampoules;Sterile Vials

Current Capacity:

We have seven sterile manufacturing lines and are rapidly expanding. We have the civil work ready for 20 manufacturing lines. Current capacity is around 150 batches per month.